V
Valneva
A biotech company developing and commercializing vaccines for infectious diseases with major unmet needs
About Valneva
Valneva SE is a specialty vaccine company that focuses on developing, manufacturing, and commercializing vaccines to prevent infectious diseases that currently lack effective treatments. The company operates in the healthcare sector, specifically within the vaccine market, and targets diseases with significant unmet medical needs. Valneva's portfolio includes vaccines in development for Lyme disease, COVID-19, and chikungunya, among others.
Read full description
Valneva serves a diverse range of clients, including healthcare providers, governments, and international organizations. The company is also a trusted partner in travel health, offering a unique range of travel vaccines and educational programs for healthcare professionals. This focus on travel health helps protect travelers by providing vaccines and increasing awareness about travel-related diseases.
The business model of Valneva revolves around the research and development (R&D) of new vaccines, followed by their manufacturing and commercialization. The company generates revenue through the sale of its vaccines to healthcare providers and governments. Additionally, Valneva may receive funding and grants from public health organizations to support its R&D efforts.
Valneva's expertise in rapidly advancing vaccine candidates through clinical trials has allowed it to commercialize three vaccines and maintain a robust pipeline of potential new products. The company is committed to ensuring access to healthcare and patient safety, aligning with its Environmental, Social, and Governance (ESG) commitments.
In summary, Valneva SE is a key player in the vaccine industry, addressing critical public health needs with innovative solutions.
At a glance
- Founded
- 1999
- Headquarters
- Saint-Herblain, France
- Listing
- IPO 2013
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Scottish Enterprise Growth Investments
Coalition for Epidemic Preparedness
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
24 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Valneva on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Valneva on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.